News >

Lurbinectedin Monotherapy Elicits Responses in Relapsed SCLC

Gina Columbus @ginacolumbusonc
Published: Monday, Mar 25, 2019

lung cancer
Lurbinectedin as monotherapy was found to elicit responses in patients with relapsed small cell lung cancer (SCLC), meeting the primary endpoint of a phase II trial by both investigator review and an independent review committee.1

 

References

  1. PharmaMar announces positive results in its lurbinectedin monotherapy trial for small cell lung cancer. PharmaMar. Published March 25, 2019. https://bit.ly/2HSnMvC. Accessed March 25, 2019.
  2. Trigo JM, Leary A, Besse B, et al. Efficacy and safety of lurbinectedin (PM1183, ZEPSYRE) in small cell lung cancer (SCLC): results from a phase 2 study. J Clin Oncol. 2018;36 (suppl; abstr 8570). doi: 10.1200/JCO.2018.36.15_suppl.8570.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication
x